Akero Therapeutics Inc (AKRO)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akero Therapeutics Inc chart...

About the Company

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Exchange

NASDAQ

Website

https://www.akerotx.com/

$M

Total Revenue

39

Employees

$1B

Market Capitalization

-9.69

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKRO News

Akero Therapeutics' Stock Is Soaring Monday - Here's Why

14d ago, source: Benzinga on MSN

Akero Therapeutics Inc (NASDAQ:AKRO) shares are trading higher after the company released preliminary topline week 96 results ...

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

13d ago, source: Zacks.com on MSN

Akero Therapeutics, Inc. AKRO announced a statistically significant histological improvement in the primary endpoint of its ...

Akero Therapeutics, Inc.

13d ago, source: CNN

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX) ...

2 Bay Area biotechs look to raise collective $550 million following deal, trial news

14d ago, source:

These Bay Area biotechs are hoping to raise $550 million between them on the back of some positive news developments. Here's ...

Akero Therapeutics Commences Public Offering Of $300 Mln Of Shares

14d ago, source:

Akero Therapeutics Inc. (AKRO) said that it has commenced an underwritten public offering of $300.0 million of shares of its common ...

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

13d ago, source:

J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

14d ago, source:

EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the ...

Akero Therapeutics Stock (NASDAQ:AKRO), Quotes and News Summary

3d ago, source: Benzinga.com

Akero Therapeutics success in HARMONY Phase 2b study ... Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market trading. Avi Kapoor Why MercadoLibre Shares ...

Akero Therapeutics Inc.: Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

11d ago, source: Finanznachrichten

March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced ...

Akero Therapeutics Inc AKRO

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

13d ago, source: Nasdaq

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics Announces Proposed Public Offering of Common Stock

15d ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...